Yan Ruyu, Song Tieying, Wang Wenli, Tian Jun, Ma Xiaojing
Department of Anesthesiology, Hebei Medical University, Shijiazhuang, Hebei, China.
Department of Anesthesiology, Shijiazhuang Traditional Chinese Medicine Hospital, Shijiazhuang, Hebei, China.
Immunopharmacol Immunotoxicol. 2023 Apr;45(2):153-159. doi: 10.1080/08923973.2022.2122501. Epub 2022 Sep 13.
Anesthetics are emerging regulators of cancer progression. Here we aim to explore the immunomodulatory roles of two common anesthetics, propofol and sevoflurane in breast cancer progression.
On murine 4T1 breast cancer models, we isolated immune cells from peripheral blood after treatment with propofol and sevoflurane during tumor resection. The CD3, CD4, and CD8 expression of these immune cells were compared using flow cytometry to determine which immune cells were prominently affected by propofol and sevoflurane. Serum cytokine levels were determined using enzyme-linked immunosorbent assay (ELISA). Metastases in lung and liver tissues were counted. In MDA-MB-231 tumor models, the cell count of immune cells was determined. The cytotoxicity of T cells and natural killing cells in co-culture after propofol and sevoflurane treatment were determined using the LDH assay.
In the 4T1 breast cancer model, T-lymphocytes showed significant cell count reduction. TNF-α was significantly upregulated at 3 and 24 h after treatment, while IL-2 and IFN-γ showed transient upregulation at 3 h after treatment. Propofol and sevoflurane increased the number of metastases in the lung and liver after primary tumor resection. In the MDA-MB-231 tumor model, CD3 and CD4 cells were also prominently reduced by propofol and sevoflurane treatment. , the proliferation and cell-killing activity of T cells and NK cells were also attenuated.
Propofol and sevoflurane had significant effects in modulating cancer progression through their immunosuppressive role. The proliferation and killing activity of anti-tumor immune cells can be suppressed by propofol and sevoflurane.
麻醉剂是癌症进展中新兴的调节因子。在此，我们旨在探讨两种常见麻醉剂丙泊酚和七氟醚在乳腺癌进展中的免疫调节作用。
在小鼠4T1乳腺癌模型中，我们在肿瘤切除过程中用丙泊酚和七氟醚处理后，从外周血中分离免疫细胞。使用流式细胞术比较这些免疫细胞的CD3、CD4和CD8表达，以确定哪些免疫细胞受丙泊酚和七氟醚的影响最为显著。使用酶联免疫吸附测定（ELISA）测定血清细胞因子水平。对肺和肝组织中的转移灶进行计数。在MDA-MB-231肿瘤模型中，确定免疫细胞的细胞计数。使用乳酸脱氢酶（LDH）测定法确定丙泊酚和七氟醚处理后共培养的T细胞和自然杀伤细胞的细胞毒性。
在4T1乳腺癌模型中，T淋巴细胞的细胞计数显著减少。治疗后3小时和24小时，肿瘤坏死因子-α（TNF-α）显著上调，而白细胞介素-2（IL-2）和干扰素-γ（IFN-γ）在治疗后3小时出现短暂上调。丙泊酚和七氟醚在原发性肿瘤切除后增加了肺和肝中的转移灶数量。在MDA-MB-231肿瘤模型中，丙泊酚和七氟醚处理也显著减少了CD3和CD4细胞。此外，T细胞和自然杀伤细胞的增殖及细胞杀伤活性也减弱。
丙泊酚和七氟醚通过其免疫抑制作用对癌症进展具有显著影响。丙泊酚和七氟醚可抑制抗肿瘤免疫细胞的增殖和杀伤活性。
